115 results
Page 3 of 6
POSASR
jm5rf
3 Mar 22
Automatic shelf registration (post-effective amendment)
7:00am
8-K
EX-99.1
lhndufl2q
11 Feb 22
Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium
11:00am
8-K
EX-99.2
k8pe d1gl
11 Feb 22
Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium
11:00am
8-K
EX-99.1
2kozhmpib8xabygk
10 Jan 22
Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline
8:00am
8-K
EX-99.2
8pfe6t as
10 Jan 22
Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline
8:00am
8-K
EX-99.2
qlhwe1bx i3x359p
17 Dec 21
Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis
7:01am
8-K
EX-99.1
7j5b246nvj
17 Dec 21
Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis
7:01am
8-K
EX-99.2
wmplj9qeda2g vc
4 Nov 21
Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business Highlights
8:00am
8-K
EX-99.1
x283opr8c8o3g9srjn
4 Nov 21
Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business Highlights
8:00am
8-K
EX-99.1
wqhjtsuzoit012k32
4 Oct 21
Regulation FD Disclosure
7:31am
8-K
EX-99.1
p9ccd
5 Aug 21
Passage Bio Reports Second Quarter 2021 Financial Results and Provides Recent Business Highlights
7:01am
8-K
EX-99.2
iwzpdw060sij8c
5 Aug 21
Passage Bio Reports Second Quarter 2021 Financial Results and Provides Recent Business Highlights
7:01am
8-K
EX-99.1
ysg nu02egda2
5 May 21
Passage Bio Reports First Quarter 2021 Financial Results and Recent Business Highlights
7:00am
8-K
EX-99.2
ahdi02 j8o40
5 May 21
Passage Bio Reports First Quarter 2021 Financial Results and Recent Business Highlights
7:00am
DEF 14A
ywe6bahw0p53oda7nikf
14 Apr 21
Definitive proxy
4:01pm